-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$41.00426.32% Upside
Recent Analyst Forecasts and Stock Ratings
4D Molecular Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover 4D Molecular Therapeutics, Inc.?
4D Molecular Therapeutics, Inc. has been rated by research analysts at BMO Capital, Loop Capital Markets, H.C. Wainwright, RBC Capital, Barclays, Jefferies in the past 90 days.